📚 JIDAM — Open Access Dental Journal|ISSN: 2582-0559|IDA Madras
EditorReviewerAuthor
J
JIDAM
JIDAM
Journal of Indian Dental Association Madras
Open AccessPeer-ReviewedFree to Publish
Home›Archives›Vol 10, Issue 1 (Jan–Mar 2022)›Article 001
JIDAM · Vol 10, Issue 1 · January–March 2022
Original Research

Dental Implants in Breast Cancer Patients Receiving Bisphosphonate Therapy

Mai Ashraf Tslaat
Faculty of Dentistry, October University for Modern Sciences and Arts, 6th of October City, Cairo, Egypt
Vol 10 · Issue 1 · 2022 DOI: 10.37841/jidam.2022.v10.i1.001 🔓 Open Access 📅 2022
1
Author
32
References
2022
Year Published
📝Abstract

This review article aims to assess the success of dental implants in breast cancer patients receiving bisphosphonate therapy, and to evaluate the risk of developing bisphosphonate related osteonecrosis of the jaw following dental implant surgery. Breast cancer patients undergoing bisphosphonate therapy may receive dental implants. However, the risk of developing BRONJ and implant failure is quite high. Risk factors such as the type of BP received, the route of administration, and the length of treatment prior to surgery should be considered.

Keywords: Dental Implants, Breast Cancer, Bisphosphonates, Osteonecrosis, Bisphosphonate-related osteonecrosis of the jaw
Received: 07 Jan 2023  |  Accepted: 14 Feb 2023
🔖How to Cite
Tslaat MA. Dental Implants in Breast Cancer Patients Receiving Bisphosphonate Therapy. J Indian Dent Assoc Madras. 2022;10(1). DOI: 10.37841/jidam.2022.v10.i1.001
Tslaat, M. A. (2022). Dental Implants in Breast Cancer Patients Receiving Bisphosphonate Therapy. Journal of Indian Dental Association Madras, 10(1). https://doi.org/10.37841/jidam.2022.v10.i1.001
Tslaat, Mai Ashraf. "Dental Implants in Breast Cancer Patients Receiving Bisphosphonate Therapy." Journal of Indian Dental Association Madras, vol. 10, no. 1, 2022. DOI: 10.37841/jidam.2022.v10.i1.001.
Tslaat MA. Dental Implants in Breast Cancer Patients Receiving Bisphosphonate Therapy. J Indian Dent Assoc Madras. 2022;10(1). doi:10.37841/jidam.2022.v10.i1.001
Tslaat, Mai Ashraf. "Dental Implants in Breast Cancer Patients Receiving Bisphosphonate Therapy." Journal of Indian Dental Association Madras 10, no. 1 (2022). https://doi.org/10.37841/jidam.2022.v10.i1.001.
📚References
  1. National Institutes of Health; National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html. Accessed January 13, 2023.
  2. Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Arch. 2022 Jan;480(1):85-93. doi: 10.1007/s00428-021-03190-7.
  3. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017 Nov 1;13(11):1387-1397. doi: 10.7150/ijbs.21635.
  4. Tahara RK, Brewer TM, Theriault RL, Ueno NT. Bone Metastasis of Breast Cancer. Adv Exp Med Biol. 2019;1152:105-129. doi: 10.1007/978-3-030-20301-6_7.
  5. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone Metastases: An Overview. Oncol Rev. 2017 May 9;11(1):321. doi: 10.4081/oncol.2017.321.
  6. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005 May;26(3):331-45. doi: 10.1210/er.2004-0015.
  7. Lønning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011 Mar;22(3):503-514. doi: 10.1093/annonc/mdq337.
  8. Ratre P, Mishra K, Dubey A, Vyas A, Jain A, Thareja S. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch. Anticancer Agents Med Chem. 2020;20(17):1994-2004. doi: 10.2174/1871520620666200627204105.
  9. Bundred NJ. Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol. 2009 Feb;21(1):60-7. doi: 10.1097/GCO.0b013e32831da80e.
  10. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park). 2006 Aug;20(9):1029-39.
  11. Chlebowski RT, Col N. Bisphosphonates and breast cancer incidence and recurrence. Breast Dis. 2011;33(2):93-101. doi: 10.3233/BD-2010-0324.
  12. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2002;(1):CD003474. doi: 10.1002/14651858.CD003474.
  13. Goldvaser H, Amir E. Role of Bisphosphonates in Breast Cancer Therapy. Curr Treat Options Oncol. 2019 Mar 14;20(4):26. doi: 10.1007/s11864-019-0623-8.
  14. Korde LA, Doody DR, Hsu L, Porter PL, Malone KE. Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):165-173. doi: 10.1158/1055-9965.EPI-17-0556.
  15. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007 Jan;4(1):42-55. doi: 10.1038/ncponc0688.
  16. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008 Sep;83(9):1032-45. doi: 10.4065/83.9.1032.
  17. Zhao X, Hu X. Dosing of zoledronic acid with its anti-tumor effects in breast cancer. J Bone Oncol. 2015 Oct 3;4(3):98-101. doi: 10.1016/j.jbo.2015.08.001.
  18. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001 Apr 20;84(8):1126-34. doi: 10.1054/bjoc.2001.1727.
  19. van de Ven S, Kroep JR, Hamdy NA, Sleeboom HP, Nortier HW. Antitumoreffect van bisfosfonaten bij mammacarcinoom [Antitumour effects of bisphosphonates in breast cancer]. Ned Tijdschr Geneeskd. 2010;154:A1951.
  20. Gupta M, Gupta N. Bisphosphonate Related Jaw Osteonecrosis. 2022 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
  21. AlRowis R, Aldawood A, AlOtaibi M, Alnasser E, AlSaif I, Aljaber A, Natto Z. Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies. Saudi Dent J. 2022 Mar;34(3):202-210. doi: 10.1016/j.sdentj.2022.01.003.
  22. Pardo-Zamora G, Martínez Y, Moreno JA, Ortiz-Ruíz AJ. Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series. Int J Environ Res Public Health. 2021 Jan 24;18(3):1018. doi: 10.3390/ijerph18031018.
  23. Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009 Jul;84(7):632-7. doi: 10.1016/S0025-6196(11)60752-0.
  24. Touil D, Fraj R, Grira I. Dental Implants in A Patient with History of Zoledronate Therapy: A Challenging Case. Journal of Dental Science Research Reviews & Reports. 2021;1-4. doi: 10.47363/JDSR/2021(3)121.
  25. Favia G, Tempesta A, Limongelli L, Crincoli V, Piattelli A, Maiorano E. Metastatic Breast Cancer in Medication-Related Osteonecrosis Around Mandibular Implants. Am J Case Rep. 2015 Sep 15;16:621-6. doi: 10.12659/AJCR.894162.
  26. Marín-Fernández AB, García Medina B, Aguilar-Salvatierra A, Jiménez-Burkhardt A, Gómez-Moreno G. Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid. J Clin Exp Dent. 2015 Jul 1;7(3):e444-6. doi: 10.4317/jced.52234.
  27. Tam Y, Kar K, Nowzari H, Cha HS, Ahn KM. Osteonecrosis of the jaw after implant surgery in patients treated with bisphosphonates--a presentation of six consecutive cases. Clin Implant Dent Relat Res. 2014 Oct;16(5):751-61. doi: 10.1111/cid.12048.
  28. Kim HJ, Park TJ, Ahn KM. Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases. Maxillofac Plast Reconstr Surg. 2016 Feb 1;38(1):6. doi: 10.1186/s40902-016-0052-6.
  29. Matsuo A, Hamada H, Takahashi H, Okamoto A, Kaise H, Chikazu D. Evaluation of dental implants as a risk factor for the development of bisphosphonate-related osteonecrosis of the jaw in breast cancer patients. Odontology. 2016 Sep;104(3):363-71. doi: 10.1007/s10266-015-0207-4.
  30. Suvarna S, Dutt P, Misra A, Usmani N, Singh A, Suvarna C. Intricate Assessment and Evaluation of Dental Implants in Patients on Bisphosphonate Therapy: A Retrospective Analysis. J Contemp Dent Pract. 2016 May 1;17(5):414-7. doi: 10.5005/jp-journals-10024-1864.
  31. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008 Feb;66(2):223-30. doi: 10.1016/j.joms.2007.09.019.
  32. Sverzut CE, Sverzut AT, de Matos FP, Kato RB, Trivellato AE, de Oliveira PT. Mandibular bisphosphonate-related osteonecrosis after dental implant rehabilitation: a case report. Implant Dent. 2012 Dec;21(6):449-53. doi: 10.1097/ID.0b013e3182703c4f.